---
title: "Hepion Pharmaceuticals acquires ctRNA biomarker assay to detect liver cancer early, with possible applications for other solid tumors."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/277623934.md"
description: "A cutting-edge non-invasive diagnostic platform for solid tumor types, including liver cancer, has the potential for applications in a wide range of other tumors. This next-generation platform is poised to revolutionize diagnostics with its innovative approach. It offers a promising alternative for patients, with the potential to improve detection rates and treatment outcomes. This advancement signifies a significant leap forward in the medical field, with the ability to impact numerous individuals affected by various types of solid tumors."
datetime: "2026-03-03T12:36:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/277623934.md)
  - [en](https://longbridge.com/en/news/277623934.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/277623934.md)
---

# Hepion Pharmaceuticals acquires ctRNA biomarker assay to detect liver cancer early, with possible applications for other solid tumors.

A cutting-edge non-invasive diagnostic platform for solid tumor types, including liver cancer, has the potential for applications in a wide range of other tumors. This next-generation platform is poised to revolutionize diagnostics with its innovative approach. It offers a promising alternative for patients, with the potential to improve detection rates and treatment outcomes. This advancement signifies a significant leap forward in the medical field, with the ability to impact numerous individuals affected by various types of solid tumors.

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [HEPA.US](https://longbridge.com/en/quote/HEPA.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)

## Related News & Research

- [BioNTech Reports Phase 1/2a Study Data For BNT323/DB-1303 In HER2-Expressing Endometrial Cancer](https://longbridge.com/en/news/282508084.md)
- [Should Positive Elsunersen Data And Relutrigine Priority Review Shift the Narrative for Praxis (PRAX) Investors?](https://longbridge.com/en/news/282419526.md)
- [PolyPid To Present New Phase 3 SHIELD II Data On D-PLEX100 At ESCMID 2026](https://longbridge.com/en/news/282665678.md)
- [Dogwood Therapeutics says FDA accepts IND for SP16 chemotherapy-induced neuropathy trial](https://longbridge.com/en/news/282850173.md)
- [Avant Brands Reports Q1 2026 Results Highlighted by 37% Growth in Recreational Revenue | AVTBF Stock News](https://longbridge.com/en/news/282741678.md)